Gilead Sciences, Ping An Ventures, Be The Match BioTherapies and existing investor Lilly Ventures Asia all backed the immunotherapy developer's series A round.

US-based immunotherapy developer Tmunity Therapeutics completed a $100m series A round today featuring biopharmaceutical company Gilead Sciences, insurance firm Ping An, pharmaceutical firm Eli Lilly and cellular research provider Be The Match BioTherapies.

University of Pennsylvania and Parker Institute for Cancer Immunotherapy also participated in the round. Ping An and Eli Lilly invested through subsidiaries Ping An Ventures and Lilly Asia Ventures respectively.

Tmunity is developing T cell immunotherapy treatments for patients suffering from cancer, infectious diseases and autoimmune diseases…